To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
5,952 Current news from the industry pharma
rss
PRAC recommends restricting the use of flupirtine-containing medicines
Committee also recommends weekly monitoring of patients’ liver function
19-06-2013
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of flupirtine-containing medicines and recommended restrictions in their use. The Committee recommended that oral flupirtine medicines and suppositories should only be used to treat acute (short-term) pain ...
PRAC recommends restricting the use of codeine when used for pain relief in children
18-06-2013
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended a series of measures to address safety concerns with codeine-containing medicines when used for the management of pain in children. This follows the PRAC’s review of reports of children who ...
PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors
17-06-2013
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the effects of the painkiller diclofenac on the heart and circulation when given systemically (by means such as capsules, tablets or injections) are similar to those of selective COX-2 ...
Resolutions of the Annual General Meeting of Evotec
14-06-2013
Shareholders of Evotec AG approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting. The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the Company's performance for the year 2012 and ...
New sickle cell anemia therapy advances to Phase II clinical trials
13-06-2013
Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase ...
DHL launches industry-changing temperature controlled Life Sciences air freight service
DHL Thermonet for temperature controlled air freight services for the Life Sciences and Healthcare sector
11-06-2013
DHL Global Forwarding launches DHL Thermonet, a new air freight product tailored to the Life Sciences and Healthcare sector. This global service is a new addition to DHL’s network of Life Sciences and Healthcare facilities and offers customers a transparent and a regulatory compliant platform ...
European Medicines Agency and EUnetHTA review progress of their cooperation
Focus on facilitation of development plans through advice procedures
10-06-2013
The European Medicines Agency (EMA) and EUnetHTA, the European network for Health Technology Assessment (HTA), met to review the progress of their cooperation in London on 14 May 2013. This was the sixth meeting since the start of their collaboration in 2010. The focus of this meeting was on ...
New screening technique paves the way for protein drugs from bacteria
06-06-2013
A cheaper, more efficient technique for developing complex protein drugs from bacteria has been developed at the University of Sheffield. Using the bacterium E. coli, researchers from the University's Faculty of Engineering showed it was possible to vastly increase the efficiency of the cells ...
EMA recommends approval of pomalidomide for the treatment of multiple myeloma
CHMP recommends measures to minimise risk of exposure to unborn babies
05-06-2013
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pomalidomide Celgene (pomalidomide) to treat patients with multiple myeloma. Multiple myeloma is a rare and incurable cancer of the bone marrow that primarily ...
Oral almitrine to be withdrawn by EU Member States
PRAC recommendation will be directly implemented following CMDh consensus
04-06-2013
The Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), a medicines regulatory body representing the EU Member States, has endorsed the recommendation by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), that permission to market oral medicines ...
Netmeeting
